Adage Capital Partners
MRVI icon

Adage Capital Partners’s Maravai LifeSciences MRVI Stock Holding History

Adage Capital Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$716K – 917
2024
Q2 		$716K Buy
+100,000
New +$863K ﹤0.01% 809
2021
Q1 		– Sell
-300,000
Closed -$8.41M – 996
2020
Q4 		$8.41M Buy
+300,000
New +$8.35M 0.02% 625

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Adage Capital Partners's MRVI Position: Q3 2024 in Review

Adage Capital Partners sold out of Maravai LifeSciences (MRVI) in Q3 2024, closing a stake of 100,000 shares — an estimated $716K sold.

Adage Capital Partners first reported a position in MRVI in Q4 2020 and held it in 2 quarters. The position peaked at $8.41M in Q4 2020. 217 funds tracked by Wall St. Rank hold MRVI as of Q3 2024.

  • Adage Capital Partners reported no remaining Maravai LifeSciences position as of Q3 2024 after selling out during the quarter.
  • Adage Capital Partners sold 100,000 Maravai LifeSciences shares in Q3 2024, an estimated $716K.
  • Adage Capital Partners first reported a position in Maravai LifeSciences in Q4 2020 and held it in 2 quarters.
  • Adage Capital Partners's Maravai LifeSciences position peaked at $8.41M in Q4 2020.
  • 217 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2024.

Based on Adage Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.